Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta

Blood (2021) 138 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2021-147292

Published: 2021

Journal Articles

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Michel Delforge, Nina Shah, MD, Paula Rodriguez-Otero, Parameswaran Hari, MD MRCP, Julia Braverman, PhD, Andrew Trigg, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136677

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Nathan Martin, PhD, Ethan G. Thompson, PhD, Will Brown, MS, Olivia Finney, PhD, Julie Rytlewski, PhD, Yue Jiang, PhD, Dipen Sangurdekar, PhD, Julie Wang, PharmD, PhD, Hans Bitter, PhD, Ronald J. Hause, Jr., PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Shari Kaiser, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134378

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134324

Published: 2020

Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134369

Published: 2020

Journal Articles

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Nina Shah, MD, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, MD MRCP, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136730

Published: 2020

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD

Blood (2019) 134 (Supplement_1): 1320.

https://doi.org/10.1182/blood-2019-125363

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger

Blood (2019) 134 (Supplement_1): 143.

https://doi.org/10.1182/blood-2019-122895

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD

Blood (2019) 134 (Supplement_1): 4328.

https://doi.org/10.1182/blood-2019-124998

Published: 2019

Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 449.

https://doi.org/10.1182/blood-2018-99-110213

Published: 2018

Journal Articles

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Nina Shah, MD, Melissa Alsina, MD, David S Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L Kaufman, MD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Kristen Hege, MD, Fabio Petrocca, MD, Jesus G. Berdeja, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 488.

https://doi.org/10.1182/blood-2018-99-116953

Published: 2018

NARROW

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only